The U.S. Ventral Hernia Mesh Devices Market was valued at USD 356.7 million in 2024, and is projected to reach USD 569.5 million by 2030, rising at a CAGR of 8.27%. The increasing cases of hernias, technological advancements in mesh repair, a shift towards preventive healthcare, growing preference for minimally invasive procedures, and a growing healthcare infrastructure are the factors affecting market growth. According to the U.S. FDA, over a million hernia repair procedures are performed annually in the U.S.
Hernia repair is one of the most common surgical procedures worldwide. The incidence of hernia is higher in men than in women. According to the International Journal of Surgery, approximately 300,000 ventral hernia repairs are performed annually. Among these, 75% are primary ventral hernia repairs (mainly epigastric and umbilical) and 25% are incisional hernia repairs. Furthermore, incisional hernias are common in nearly 10-30% of patients in the U.S. who undergo midline laparotomies. The annual costs for hernia repairs are estimated at approximately USD 3.2 billion. This is viewed as a major healthcare challenge for patients and a significant financial hurdle for the U.S. healthcare system.
The presence of favorable reimbursement scenarios for hernia mesh devices is encouraging patients to opt for surgery. The government and industry players provide patients with easy access to detailed reimbursement codes and ratios. The codes are granulated into types of hernias (primary or recurrent) and surgery methods (open or laparoscopic).
Technological advancements in hernia mesh devices have significantly improved patient outcomes and reduced complications. One notable innovation is the development of lightweight and composite meshes. These meshes, such as Parietex Composite Mesh, combine absorbable and nonabsorbable materials, providing strength while reducing postoperative discomfort and the risk of chronic pain. These advancements include innovations like Deep Blue Medical Advances, Inc.’s advanced mesh technology. In 2024, the company launched a smaller version of the T-Line Mesh, known as the T-Line Mini, tailored for umbilical hernias and small defects. Moreover, the T-Line Hernia Mesh's coated and biosynthetic composite versions are developing.
This product will be delivered within 1-3 business days.
Hernia repair is one of the most common surgical procedures worldwide. The incidence of hernia is higher in men than in women. According to the International Journal of Surgery, approximately 300,000 ventral hernia repairs are performed annually. Among these, 75% are primary ventral hernia repairs (mainly epigastric and umbilical) and 25% are incisional hernia repairs. Furthermore, incisional hernias are common in nearly 10-30% of patients in the U.S. who undergo midline laparotomies. The annual costs for hernia repairs are estimated at approximately USD 3.2 billion. This is viewed as a major healthcare challenge for patients and a significant financial hurdle for the U.S. healthcare system.
The presence of favorable reimbursement scenarios for hernia mesh devices is encouraging patients to opt for surgery. The government and industry players provide patients with easy access to detailed reimbursement codes and ratios. The codes are granulated into types of hernias (primary or recurrent) and surgery methods (open or laparoscopic).
Technological advancements in hernia mesh devices have significantly improved patient outcomes and reduced complications. One notable innovation is the development of lightweight and composite meshes. These meshes, such as Parietex Composite Mesh, combine absorbable and nonabsorbable materials, providing strength while reducing postoperative discomfort and the risk of chronic pain. These advancements include innovations like Deep Blue Medical Advances, Inc.’s advanced mesh technology. In 2024, the company launched a smaller version of the T-Line Mesh, known as the T-Line Mini, tailored for umbilical hernias and small defects. Moreover, the T-Line Hernia Mesh's coated and biosynthetic composite versions are developing.
U.S. Ventral Hernia Mesh Devices Market Report Segmentation
This report forecasts country-level revenue growth and analyzes the latest industry trends and opportunities in each sub-segment from 2018 to 2030. For this study, the analyst has segmented the U.S. ventral hernia mesh devices market report based on mesh type, indication, procedure, and end use:Mesh Type Outlook (Revenue, USD Million, 2018-2030)
- Resorbable Mesh
- Partially Absorbable Mesh
- Non-resorbable Mesh
Indication Outlook (Revenue, USD Million 2018-2030)
- Umbilical Hernia
- Epigastric Hernia
- Incisional Hernia
- Others
Procedure Outlook (Revenue, USD Million 2018-2030)
- Open Surgery
- Laparoscopic Surgery
- Robotic Surgery
- Others
End Use Outlook (Revenue, USD Million 2018-2030)
- Inpatient Facilities
- Outpatient Facilities
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Ventral Hernia Mesh Devices Market Variables, Trends & Scope
Chapter 4. U.S. Ventral Hernia Mesh Devices Market: Mesh Type Estimates & Trend Analysis
Chapter 5. U.S. Ventral Hernia Mesh Devices Market: Indication Estimates & Trend Analysis
Chapter 6. U.S. Ventral Hernia Mesh Devices Market: Procedure Estimates & Trend Analysis
Chapter 7. U.S. Ventral Hernia Mesh Devices Market: End-use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this U.S. Ventral Hernia Mesh Devices market report include:- Medtronic plc
- Becton, Dickinson and Company
- Ethicon Inc. (Johnson & Johnson MedTech)
- Meril Life Sciences Pvt. Ltd.
- Novus Scientific AB
- B. Braun SE
- TELA Bio, Inc.
- BG Medical LLC
- Integra LifeSciences Corporation
- W. L. Gore & Associates, Inc.
- Atrium Medical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 356.7 Million |
| Forecasted Market Value ( USD | $ 569.5 Million |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | United States |
| No. of Companies Mentioned | 12 |
